• Users Online: 347
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2021  |  Volume : 46  |  Issue : 2  |  Page : 70-74

Pulmonary hypertension as a risk factor in JAK2-positive polycythemia rubra vera


1 Haematology Unit, Department of Internal Medicine, Faculty of Medicine, South Valley University, Qena, Egypt
2 Department of Chest Diseases and Tuberculosis, Faculty of Medicine, South Valley University, Qena, Egypt
3 Department of Clinical Pathology, Faculty of Medicine, Assiut University, Assiut; Department of Clinical and Chemical Pathology, Qena Faculty of Medicine, South Valley University, Qena, Egypt
4 Department of Internal Medicine, Faculty of Medicine, South Valley University, Qena, Egypt
5 Cardiology Division, Department of Internal Medicine, Faculty of Medicine, South Valley University, Qena, Egypt
6 Department of Internal Medicine, Faculty of Medicine, South Valley University, Qena; Department of Internal Medicine, Arabian Gulf University (AGU), Bahrain, Egypt

Correspondence Address:
Asmaa Nafady
Clinical and Chemical Pathology, Qena Faculty of Medicine, South Valley University, Qena, Department of Clinical Pathology, Faculty of Medicine, Assiut University, Assiut, 83523
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ejh.ejh_9_21

Rights and Permissions

Introduction The occurrence of primary pulmonary arterial hypertension (PAH (in primary myeloid proliferation neoplasms seems quite high, up to 22% in polycythemia vera. Polycythemia rubra vera (PRV) is one of the myeloproliferative neoplasms. We aimed to study the incidence of PAH among patients with PRV. Patients and methods A prospective cross-section study was performed on 60 (PRV) patients with PRV confirmed by bone marrow and JAK2 positivity. Abdominal ultrasonography, transthoracic echocardiography, and computed tomography chest were done to estimate the pulmonary hypertension (HTN) and exclude other chest diseases. Results Among the studied 60 patients, we found 14 patients with pulmonary HTN (23.4%) who had significantly increased incidence of comorbidities than patients with normal pulmonary pressure (P=0.009). Moreover, there were statistically significant differences in the size of spleen by ultrasound between the two groups (P=0.008). Patients with pulmonary HTN had a higher hemoglobin level compared with those with normal pulmonary pressure (P=0.006). There was a significant positive correlation between pulmonary pressure and existing comorbidities (diabetes mellitus, HTN, or both) but no correlation with the size of the spleen, hemoglobin level, or white blood cells. Conclusion The prevalence of PAH in JAK2-positive patients with PRV is 76.6%, and there was significant relationship between hematological parameters (hemoglobin, white blood cells, lactate dehydrogenase, and urea level and PAH in JAK2-positive patients with PRV.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1005    
    Printed18    
    Emailed0    
    PDF Downloaded84    
    Comments [Add]    

Recommend this journal